Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Fostamatinib Disodium

These are related to the Fostamatinib Disodium news, in which you can learn about the updated information in Fostamatinib Disodium, to help you better understand and expand Fostamatinib Disodium market. Because the market for Fostamatinib Disodium is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
  • Drug Patent & Exclusivity Expiration Report - Week of April 14 2025

    Drug Patent & Exclusivity Expiration Report - Week of April 14 2025

    2025-04-14

    This week, there are 6 drugs in the patent and exclusivity list. They are: - ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC's KYPROLIS, containing active ingredient CARFILZOMIB - JANSSEN PRODUCTS LP's SYMTUZA, containing active ingredient COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - INCYTE CORP's PEMAZYRE, containing active ingredient PEMIGATINIB - SEAGEN INC's TUKYSA, containing active ingredient TUCATINIB - RIGEL PHARMACEUTICALS INC's TAVALISSE, containing active ingredient FOSTAMATINIB DISODIUM - ASTRAZENECA PHARMACEUTICALS LP's TAGRISSO, containing active ingredient OSIMERTINIB MESYLATE Read More